BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 14629464)

  • 1. The plasminogen activator inhibitor-1 -675 4G/5G genotype influences the risk of myocardial infarction associated with elevated plasma proinsulin and insulin concentrations in men from Europe: the HIFMECH study.
    Juhan-Vague I; Morange PE; Frere C; Aillaud MF; Alessi MC; Hawe E; Boquist S; Tornvall P; Yudkin JS; Tremoli E; Margaglione M; Di Minno G; Hamsten A; Humphries SE;
    J Thromb Haemost; 2003 Nov; 1(11):2322-9. PubMed ID: 14629464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The 4G/5G polymorphism of the plasminogen activator inhibitor gene is associated with the time course of progression to acute coronary syndromes.
    Iwai N; Shimoike H; Nakamura Y; Tamaki S; Kinoshita M
    Atherosclerosis; 1998 Jan; 136(1):109-14. PubMed ID: 9544737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasminogen activator inhibitor-1 4G/5G gene polymorphism in patients with myocardial or cerebrovascular infarction in Tianjin, China.
    Zhan M; Zhou Y; Han Z
    Chin Med J (Engl); 2003 Nov; 116(11):1707-10. PubMed ID: 14642142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of PAI-1 4G/5G and -844G/A gene polymorphisms and changes in PAI-1/tissue plasminogen activator levels in myocardial infarction: a case-control study.
    Abboud N; Ghazouani L; Saidi S; Ben-Hadj-Khalifa S; Addad F; Almawi WY; Mahjoub T
    Genet Test Mol Biomarkers; 2010 Feb; 14(1):23-7. PubMed ID: 19929406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduced carriership of 4G allele of plasminogen activator inhibitor-1 4G/5G polymorphism in very young survivors of myocardial infarction.
    Rallidis LS; Gialeraki A; Merkouri E; Liakos G; Dagres N; Sionis D; Travlou A; Lekakis J; Kremastinos DT
    J Thromb Thrombolysis; 2010 May; 29(4):497-502. PubMed ID: 19844663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasminogen activator inhibitor-1 4G4G genotype is associated with myocardial infarction but not with stable coronary artery disease.
    Onalan O; Balta G; Oto A; Kabakci G; Tokgozoglu L; Aytemir K; Altay C; Gurgey A; Nazli N
    J Thromb Thrombolysis; 2008 Dec; 26(3):211-7. PubMed ID: 17721742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lack of association of a common polymorphism of the plasminogen activator inhibitor-1 gene with coronary artery disease and myocardial infarction.
    Anderson JL; Muhlestein JB; Habashi J; Carlquist JF; Bair TL; Elmer SP; Davis BP
    J Am Coll Cardiol; 1999 Nov; 34(6):1778-83. PubMed ID: 10577569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Promoter (4G/5G) plasminogen activator inhibitor-1 genotype and plasminogen activator inhibitor-1 levels in blacks, Hispanics, and non-Hispanic whites: the Insulin Resistance Atherosclerosis Study.
    Festa A; D'Agostino R; Rich SS; Jenny NS; Tracy RP; Haffner SM
    Circulation; 2003 May; 107(19):2422-7. PubMed ID: 12719278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasminogen activator inhibitor-1 promoter 4G/5G genotype and plasma levels in relation to a history of myocardial infarction in patients characterized by coronary angiography.
    Ossei-Gerning N; Mansfield MW; Stickland MH; Wilson IJ; Grant PJ
    Arterioscler Thromb Vasc Biol; 1997 Jan; 17(1):33-7. PubMed ID: 9012634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The 4G/5G genetic polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene is associated with differences in plasma PAI-1 activity but not with risk of myocardial infarction in the ECTIM study. Etude CasTemoins de I'nfarctus du Mycocarde.
    Ye S; Green FR; Scarabin PY; Nicaud V; Bara L; Dawson SJ; Humphries SE; Evans A; Luc G; Cambou JP
    Thromb Haemost; 1995 Sep; 74(3):837-41. PubMed ID: 8571307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The association between plasminogen activator inhibitor type 1 (PAI-1) levels, PAI-1 4G/5G polymorphism, and myocardial infarction: a Mendelian randomization meta-analysis.
    Nikolopoulos GK; Bagos PG; Tsangaris I; Tsiara CG; Kopterides P; Vaiopoulos A; Kapsimali V; Bonovas S; Tsantes AE
    Clin Chem Lab Med; 2014 Jul; 52(7):937-50. PubMed ID: 24695040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PAI-1 Gene 4G/5G polymorphism and risk of type 2 diabetes in a population-based sample.
    Meigs JB; Dupuis J; Liu C; O'Donnell CJ; Fox CS; Kathiresan S; Gabriel SB; Larson MG; Yang Q; Herbert AG; Wilson PW; Feng D; Tofler GH; Cupples LA
    Obesity (Silver Spring); 2006 May; 14(5):753-8. PubMed ID: 16855181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PAI-1 level and the PAI-1 4G/5G polymorphism in relation to risk of non-fatal myocardial infarction: results from the Stockholm Heart Epidemiology Program (SHEEP).
    Leander K; Wiman B; Hallqvist J; Sten-Linder M; de Faire U;
    Thromb Haemost; 2003 Jun; 89(6):1064-71. PubMed ID: 12783120
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determinants of plasminogen activator inhibitor 1 activity in treated NIDDM and its relation to a polymorphism in the plasminogen activator inhibitor 1 gene.
    Panahloo A; Mohamed-Ali V; Lane A; Green F; Humphries SE; Yudkin JS
    Diabetes; 1995 Jan; 44(1):37-42. PubMed ID: 7813812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasminogen activator inhibitor-1 (PAI-1) activity post myocardial infarction: the role of acute phase reactants, insulin-like molecules and promoter (4G/5G) polymorphism in the PAI-1 gene.
    Panahloo A; Mohamed-Ali V; Gray RP; Humphries SE; Yudkin JS
    Atherosclerosis; 2003 Jun; 168(2):297-304. PubMed ID: 12801613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The plasminogen activator inhibitor-1 (PAI-1) gene -844 A/G and -675 4G/5G promoter polymorphism significantly influences plasma PAI-1 levels in women with polycystic ovary syndrome.
    Lin S; Huiya Z; Bo L; Wei W; Yongmei G
    Endocrine; 2009 Dec; 36(3):503-9. PubMed ID: 19856137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An effect of the PAI-1 4G/5G polymorphism on cholesterol levels may explain conflicting associations with myocardial infarction and stroke.
    Boncoraglio GB; Bodini A; Brambilla C; Carriero MR; Ciusani E; Parati EA
    Cerebrovasc Dis; 2006; 22(2-3):191-5. PubMed ID: 16735791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasminogen activator inhibitor-1 (PAI-1) 4G/5G polymorphism, coronary thrombosis, and myocardial infarction in middle-aged Finnish men who died suddenly.
    Mikkelsson J; Perola M; Wartiovaara U; Peltonen L; Palotie A; Penttilä A; Karhunen PJ
    Thromb Haemost; 2000 Jul; 84(1):78-82. PubMed ID: 10928474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The 4G/5G polymorphism in the plasminogen activator inhibitor-1 gene is not associated with myocardial infarction.
    Doggen CJ; Bertina RM; Cats VM; Reitsma PH; Rosendaal FR
    Thromb Haemost; 1999 Jul; 82(1):115-20. PubMed ID: 10456464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasminogen activator inhibitor-1 5G/5G genotype is associated with early spontaneous recanalization of the infarct-related artery in patients presenting with acute ST-elevation myocardial infarction.
    Cagliyan CE; Yuregir OO; Balli M; Tekin K; Akilli RE; Bozdogan ST; Turkmen S; Deniz A; Baykan OA; Aslan H; Cayli M
    Coron Artery Dis; 2013 May; 24(3):196-200. PubMed ID: 23283030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.